Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macrogol 4000 + simeticone + electrolytes is an **oral bowel-preparation combination product** used before colonoscopy, including colorectal cancer screening and surveillance. The formulation combines **macrogol 4000**, a non-absorbable polyethylene glycol osmotic laxative that retains water in the intestinal lumen to induce catharsis, with **simeticone**, an anti-foaming agent that lowers surface tension of gas bubbles and improves mucosal visualization by reducing intraluminal foam and bubbles; the **electrolytes** are included to support isotonic lavage and reduce clinically meaningful fluid and electrolyte shifts during bowel cleansing. This is not an antineoplastic therapy for colorectal cancer itself, but a supportive gastrointestinal preparation used to optimize colon cleansing and endoscopic visibility. The provided developer context appears to reflect its use in colorectal cancer screening settings rather than a uniquely branded oncology drug candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 4000 + simeticone + electrolytes.